Vorinostat Plus Radiation Therapy in Pancreatic Cancer
Status:
Terminated
Trial end date:
2010-10-01
Target enrollment:
Participant gender:
Summary
Primary Endpoint:
To determine the maximum tolerated dose (MTD) of vorinostat + radiation therapy (RT) in
patients with locally advanced pancreatic cancer (LAPC).
Secondary Endpoints:
1. To assess the efficacy of vorinostat + RT in patients with LAPC as estimated by median
overall survival.
2. To determine the radiological response as assessed by regular computer tomography (CT)
and/or dynamic contrast enhanced computer tomography (DCE-CT) among patients treated
with vorinostat and RT.
3. To evaluate the occurrence of symptoms and correlate to disease progression and
tolerance to treatment using the MD Anderson Symptom Inventory-Gastrointestinal Module
(MDASI-GI) self-reporting tool.
4. To correlate serum cytokine levels with symptoms and treatment outcomes.